FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Your study has timed out. Please make sure that you allow cookies from our site. Alternatively, this could occur if you spend more than 15…
The Los Angeles Superior Court awarded $14 million to a former UCLA oncologist Thursday following an eight-year battle over her gender discrimination lawsuit. Dr. Lauren…
View the current volume of the ASCO Educational Book
Treatment switching and other differences between review or guideline recommendation target interventions and comparators vs. interventions and comparators as implemented in otherwise relevant trials are…
Background: Artificial intelligence is increasingly being applied to many workflows. Large language models (LLMs) are publicly accessible platforms trained to understand, interact with, and produce…
From 1970 to 1990s, the NHS exposed people to tainted blood through transfusions and gave infected US blood products to haemophiliacs
Scandal was completely avoidable, with government and NHS colluding to cover up risk to patients
Expert panelists highlight the COMFORT I and COMFORT II studies.
Last Friday’s main story in the Times told us many things that we already knew. First, that there are real problems with productivity in the…
Most malignant peripheral nerve sheath tumors (MPNSTs) are clinically aggressive high-grade sarcomas, arising in individuals with neurofibromatosis type 1 (NF1) at a significantly elevated estimated…